Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Affimed Announced Saturday, In 17 EGFR Wild-type NSCLC Patients Who Failed Chemotherapy And PD-1/PD-l1, AFM24 Plus Atezolizumab Achieved 4 Objective Responses; 3 Of 4 Responses Were Ongoing For More Than 7 Months, Progression Free Survival Was 5.9 Months

Author: Charles Gross | June 02, 2024 02:43pm

Posted In: AFMD